Results of the European Glaucoma Prevention Study.

OBJECTIVE The European Glaucoma Prevention Study (EGPS) seeks to evaluate the efficacy of reduction of intraocular pressure (IOP) by dorzolamide in preventing or delaying primary open-angle glaucoma (POAG) in patients affected by ocular hypertension (OHT). DESIGN Randomized, double-masked, controlled clinical trial. PARTICIPANTS One thousand eighty-one patients (age, > or =30 years) were enrolled by 18 European centers. The patients fulfilled a series of inclusion criteria, including: IOP 22 to 29 mmHg; 2 normal and reliable visual fields (on the basis of mean deviation and corrected pattern standard deviation or corrected loss variance of standard 30/II Humphrey or Octopus perimetry); normal optic disc as determined by the Optic Disc Reading Center. INTERVENTION Patients were randomized to treatment with dorzolamide or placebo (the vehicle of dorzolamide). MAIN OUTCOME MEASURES Efficacy end points were visual field, optic disc changes, or both. A visual field change during follow-up had to be confirmed by 2 further positive tests. Optic disc change was defined on the basis of the agreement of 2 of 3 independent observers evaluating optic disc stereo slides. The safety end point was an IOP of more than 35 mmHg on 2 consecutive examinations. RESULTS During the course of the study, the mean percent reduction in IOP in the dorzolamide group was 15% after 6 months and 22% after 5 years. Mean IOP declined by 9% after 6 months and by 19% after 5 years in the placebo group. At 60 months, the cumulative probability of converting to an efficacy end point was 13.4% in the dorzolamide group and 14.1% in the placebo group (hazard ratio, 0.86; 95% confidence interval [CI], 0.58-1.26; P = 0.45). The cumulative probability of developing an efficacy or a safety end point was 13.7% in the dorzolamide group and 16.4% in the placebo group (hazard ratio, 0.73; 95% CI, 0.51-1.06; P = 0.1). CONCLUSIONS Dorzolamide reduced IOP by 15% to 22% throughout the 5 years of the trial. However, the EGPS failed to detect a statistically significant difference between medical therapy and placebo in reducing the incidence of POAG among a large population of OHT patients at moderate risk for developing POAG, because placebo also significantly and consistently lowered IOP.

[1]  G. Marchini,et al.  Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. , 2000, Ophthalmology.

[2]  Stefano Miglior,et al.  Reproducibility of evaluation of optic disc change for glaucoma with stereo optic disc photographs. , 2003, Ophthalmology.

[3]  C. Ostrov,et al.  Two‐year Safety Study of Dorzolamide as Monotherapy and with Timolol and Pilocarpine , 1998, Journal of glaucoma.

[4]  J. Beiser,et al.  Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). , 2001, Ophthalmology.

[5]  M. F. Sugrue.  Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors , 2000, Progress in Retinal and Eye Research.

[6]  W. C. Stewart,et al.  Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. , 1998, Archives of internal medicine.

[7]  David Garway-Heath,et al.  Results of the betaxolol versus placebo treatment trial in ocular hypertension , 2003, Graefe's Archive for Clinical and Experimental Ophthalmology.

[8]  N. Pfeiffer,et al.  Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. , 1997, Survey of ophthalmology.

[9]  A E Maumenee,et al.  Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. , 1980, Archives of ophthalmology.

[10]  L. Freedman.  Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.

[11]  Douglas R. Anderson,et al.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. , 1998, American journal of ophthalmology.

[12]  E. Strahlman,et al.  A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. , 1995, Archives of ophthalmology.

[13]  D. R. Anderson,et al.  Glaucoma: the damage caused by pressure. XLVI Edward Jackson memorial lecture. , 1989, American journal of ophthalmology.

[14]  J. Schuman,et al.  Antiglaucoma medications: a review of safety and tolerability issues related to their use. , 2000, Clinical therapeutics.

[15]  B. Prum,et al.  The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration , 2000 .

[16]  R. P. Mills,et al.  Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. , 2001, Ophthalmology.

[17]  A Heijl,et al.  Early Manifest Glaucoma Trial: design and baseline data. , 1999, Ophthalmology.

[18]  E. Strahlman,et al.  A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group. , 1996, American journal of ophthalmology.

[19]  L. Silver.  Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension , 1998 .

[20]  A. Sommer,et al.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. , 1991, Archives of ophthalmology.

[21]  C. Ekström,et al.  Elevated intraocular pressure and pseudoexfoliation of the lens capsule as risk factors for chronic open‐angle glaucoma , 1993, Acta ophthalmologica.

[22]  V. Torri,et al.  Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice? , 1994 .

[23]  Valter Torri,et al.  The European glaucoma prevention study design and baseline description of the participants. , 2002, Ophthalmology.

[24]  D. King,et al.  A quantifiable alternative to double data entry. , 2000, Controlled clinical trials.

[25]  M. Kass,et al.  Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. , 1989, Archives of ophthalmology.

[26]  S. Orengo-Nania,et al.  Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. , 2001, American journal of ophthalmology.

[27]  D. Epstein,et al.  A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. , 1989, Ophthalmology.

[28]  A. Sommer,et al.  Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. , 1995, Archives of ophthalmology.

[29]  E. Sharpe,et al.  Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure , 1998 .

[30]  M. C. Leske,et al.  Risk factors for open-angle glaucoma. The Barbados Eye Study. , 1995, Archives of ophthalmology.

[31]  P. Lichter,et al.  The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. , 1999, Ophthalmology.

[32]  B. Bengtsson,et al.  Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[33]  S. Drance,et al.  A comparison of treated and untreated glaucoma suspects. , 1991, Ophthalmology.

[34]  A. Sommer,et al.  Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. , 1994, Archives of ophthalmology.